Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1(VR1) receptor

1. A compound of formula (I)

or a pharmaceutically acceptable salt or prodrug thereof, wherein

— is absent or is a single bond;

X 1 is CR 1 ;

X 2 is CR 2 ;

X 3 is NR 3 ;

X 4 is a bond;

X 5 is N;

Z 1 is O;

Z 2 is NH;

L is selected from the group consisting of alkenylene, alkylene, alkynylene,

cycloalkylene,

—(CH 2 ) m O(CH 2 ) n —, and N(R Y ), wherein the left end of —(CH 2 ) m O(CH 2 ) n — is attached to Z 2 and the right end is attached to R 9 ;

m and n are each independently 1-6;

R Y is selected from the group consisting of hydrogen and alkyl;

R 1 , R 3 , R 5 , R 6 , and R 7 are each independently selected from the group consisting of hydrogen, alkoxy, alkoxyalkoxy, alkoxyalkyl, alkyl, alkylcarbonyloxy, carboxy, carboxyalkyl, cyano, cyanoalkyl, haloalkoxy, haloalkyl, haloalkylthio, halogen, hydroxy, hydroxyalkyl, NR A S(O) 2 R B , —S(O) 2 R B , —NZ A Z B , (NZ A Z B )alkyl, (NZ A Z B )carbonylalkyl and (NZ A Z B )sulfonyl, wherein Z A and Z B are each independently selected from the group consisting of hydrogen, alkyl, alkylcarbonyl, aryl, and arylalkyl;

R 2 and R 4 are each independently selected from the group consisting of hydrogen, alkoxy, alkoxyalkoxy, alkoxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, alkyl, alkylcarbonyl, alkylcarbonylalkyl, alkylcarbonyloxy, carboxy, carboxyalkyl, cyano, cyanoalkyl, cycloalkyl, cycloalkylalkyl, haloalkoxy, haloalkyl, haloalkylthio, halogen, hydroxy, hydroxyalkyl, —NR A S(O) 2 R B , —S(O) 2 OR A , —S(O) 2 R B , —NZ A Z B , (NZ A Z B )alkyl, (NZ A Z B )alkylcarbonyl, (NZ A Z B )carbonyl, (NZ A Z B )carbonylalkyl, and (NZ A Z B )sulfonyl;

R A is selected from the group consisting of hydrogen and alkyl;

R B is selected from the group consisting of alkyl, aryl, and arylalkyl;

R 8a is selected from the group consisting of hydrogen and alkyl; and

R 9 is selected from the group consisting of hydrogen, aryl, cycloalkyl, and heterocycle.

2. A compound according to claim 1 wherein

L is alkylene; and

R 9 is aryl.

3. A compound according to claim 1 wherein

R 1 , R 2 , R 5 , R 6 and R 7 are each hydrogen;

L is alkylene;

R 9 is aryl wherein said aryl is phenyl substituted with 1, 2, or 3 substituents independently selected from the group consisting of alkoxy, alkyl, alkylsulfonyl, 1-azepanyl, 1-azocanyl, cyano, haloalkoxy, haloalkyl, haloalkylthio, halogen, methylenedioxy, 4-morpholinyl, 2,6,-dimethyl-4-morpholinyl, phenyl, 1-piperidinyl, 4-methyl-1-piperidinyl, pyridinyl, 1-pyrrolidinyl, 4-thiomorpholinyl, and —NZ C Z D ; and

Z C and Z D are independently selected from the group consisting of hydrogen and alkyl.

4. A compound according to claim 3 selected from the group consisting of

N-(4-bromobenzyl)-N′-1H-indol-4-ylurea;

N-(3,4-dichlorobenzyl)-N′-1H-indol-4-ylurea;

N-1H-indol-4-yl-N′-[4-(trifluoromethyl)benzyl]urea;

N-1H-indol-4-yl-N′-[4-(trifluoromethoxy)benzyl]urea;

N-[3-fluoro-4-(trifluoromethyl)benzyl]-N′-1H-indol-4-ylurea;

1-(4-chloro-3-trifluoromethyl-benzyl)-3-(1H-indol-4-yl)-urea;

1-(4-chloro-3-trifluoromethyl)-3-(1H-indol-4-yl)-urea; and

N-[2-(2,4-dichlorophenyl)ethyl]-N′-1H-indol-4-ylurea.

5. A compound according to claim 1 wherein

R 1 and R 2 are each independently alkyl;

R 5 , R 6 and R 7 are each hydrogen;

L is alkylene;

R 9 is aryl wherein said aryl is phenyl substituted with 1, 2, or 3 substituents independently selected from the group consisting of alkoxy, alkyl, alkylsulfonyl, 1-azepanyl, 1-azocanyl, cyano, haloalkoxy, haloalkyl, haloalkylthio, halogen, methylenedioxy, 4-morpholinyl, 2,6,-dimethyl-4-morpholinyl, phenyl, 1-piperidinyl, 4-methyl-1-piperidinyl, pyridinyl, 1-pyrrolidinyl, 4-thiomorpholinyl, and —NZ C Z D ; and

Z C and Z D are independently selected from the group consisting of hydrogen and alkyl.

6. A compound according to claim 5 that is N-(4-bromobenzyl)-N′-(2,3-dimethyl-1H-indol-4-yl)urea.

7. A pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I) according to claim 1 or a pharmaceutically acceptable salt thereof.

8. A method of treating a disorder wherein the disorder is ameliorated by inhibiting vanilloid receptor subtype 1 (VR1) receptor, and wherein the disorder is selected from the group comprising pain, bladder overactivity, urinary incontinence and inflammatory hyperalgesia—in a host mammal in need of such treatment comprising administering a therapeutically effective amount of a compound of formula (I) according to claim 1 , or a pharmaceutically acceptable salt thereof.

9. The method of treating according to claim 8 , wherein the disorder is bladder overactivity.

10. The method of treating according to claim 8 , wherein the disorder is urinary incontinence.

11. The method of treating to claim 8 , wherein the disorder is pain.

12. The method of treating to claim 8 , wherein the disorder is inflammatory hyperalgesia.